Es fundamental comenzar con la dosis ms baja posible para evaluar la tolerancia del sujeto
12 These outcomes are consistent with a maintained postprandial metabolic effect but note the important confound: in these trials cagrilintide is almost always studied with semaglutide, so cleanly attributing the postprandial glucose benefit to cagrilintides gastric or glucagon effects specifically is not straightforward
Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Theres almost zero basically zero evidence in human trials, Spittler said
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, et al
Thats the main shelf of your fridge, not the door